Table 3.
SN‐5 components, median (IQR) | Conventional dosing n = 18 | Genotype‐guided dosing n = 16 | P value (unadjusted) | P valuea |
---|---|---|---|---|
Sinus infection | 2.0 (1.0–3.0) | 1.0 (1.0–2.5) | 0.201 | 0.721 |
Nasal obstruction | 2.5 (1.0–4.0) | 1.0 (1.0–2.5) | 0.170 | 0.327 |
Allergy symptoms | 3.0 (2.0–4.0) | 1.0 (1.0–2.0) | 0.007 | 0.006 |
Emotional distress | 2.5 (1.0–5.0) | 1.5 (1.0–3.0) | 0.198 | 0.528 |
Activity limitations | 1.0 (1.0–3.0) | 1.0 (1.0–1.0) | 0.092 | 0.244 |
SN‐5 score | 2.6 (2.0–3.4) | 1.8 (1.0–2.3) | 0.012 | 0.031 |
IQR, interquartile range.
Adjusted for baseline score, race, baseline proton pump inhibitor use, baseline histamine receptor antagonist use.